Project description
Genome editing to tackle immune diseases
There is an unprecedented increase in chronic diseases due to immune imbalance for which there are limited treatment options. The EU-funded geneTIGA is developing a safe and efficient cell therapy based on genome-edited T cells to sustainably combat IgA nephropathy (IgAN), one of the most common causes of end-stage renal disease. As an IgA disease, this cell therapy approach can form the blueprint for other IgA diseases including IgA myeloma, IgA related coeliac disease and rheumatoid arthritis, as well as other Ig diseases. Thus, geneTIGA researchers anticipate the delivery of a ‘living drug’ to treat IgAN and other IgA-associated diseases for entry to first-in-human clinical trials.
Fields of science
- medical and health sciencesclinical medicinerheumatology
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesmedical biotechnologycells technologies
- medical and health sciencesclinical medicinenephrologykidney diseases
- medical and health sciencesclinical medicinegastroenterology
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
10117 Berlin
Germany
See on map
Participants (8)
79106 Freiburg
See on map
38106 Braunschweig
See on map
0450 Oslo
See on map
8000 Aarhus C
See on map
13347 Berlin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
13353 Berlin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1190 Wien
See on map
53100 Siena
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (2)
8092 Zuerich
See on map
OX1 2JD Oxford
See on map